Minimal Erythema Dose
Conditions
Brief summary
This is a double-blind, randomized, placebo-controlled interventional study of the effect of multiple-dose dietary intake on minimal erythema dose and other skin parameters.
Detailed description
This is a double-blind, randomized, placebo-controlled interventional study of the effect of multiple-dose dietary intake on minimal erythema dose and other skin parameters. The study will be performed on 54 adults, between the ages 21 and 65 years and will include daily dietary supplementation over 8-weeks period. Participants will be randomly assigned in one of two groups, 27 in each. One group (test group) will receive investigational product, a syrup containing red orange extract, Calaguala extract and vitamins A, C, D, E and the other placebo syrup. Participants will continuously receive placebo or investigational product for 8 weeks in order to determine multiple-dose effects.
Interventions
DIETARY_SUPPLEMENTActive product
Contains a complex of: Calaguala leaves extract (Polypodium leucotomos), vitamin C (L-ascorbic acid), blood orange fruit extract (Citrus sinensis; red orange extract), vitamin E (alpha-tocopheryl acetate), vitamin A (retinyl palmitate), vitamin D3 cholecalciferol.
DIETARY_SUPPLEMENTPlacebo
No active ingredients.
Sponsors
VIST - Faculty of Applied Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
21 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Caucasian volunteers aged between 21 and 65 years at the time of the signature of Informed consent form (ICF), * Signed Informed consent form (ICF), * Fitzpatrick skin phototypes I-III, * No skin pigmentation disorders, * In good health condition, * Willingness to avoid a consumption of any food supplements containing red orange extract, polypodium extract, carotenes or other antioxidants that could interfere with the results during the study, * Willingness to avoid the sun, tanning beds and tanning products on the test area during the study, * Willingness to follow all study procedures and keeping a diary during the study (to follow their compliance and palatability), * No changes in dietary habits or dietary supplements in last 2 months prior to inclusion. * No changes in cosmetic body care routine in last month prior to inclusion on measurement areas. * No recent participation in any other similar study. * No sun exposure (both natural and artificial) for at least two months before study start on the test area. * Absence of sunburn, suntan, scars, or other active dermal lesions on the test area. * Colour uniformity of the test area (without tattoo, nevi, blemishes or solar lentigo and without hair).
Exclusion criteria
* Pregnancy or breastfeeding or planning pregnancy in next 6 months (for women) * Known or suspected allergy to any ingredient of the tested products or UV radiation. * Dermatological problems in the test area or the requirement for annual mole checks by a dermatologist. * Pharmacological treatments (both locally or systemically) that could interfere with the results. * Positive anamnesis for atopy (allergic hypersensitivity affecting parts of the body not in direct contact with the allergen) * Use of self-tanning products for at least 2 months before study start. * Medication with photosensitizing potential, drugs, corticoids in last month prior to study start. * Regular consumption of food supplements containing red orange extract, polypodium extract, carotenoids or other antioxidants or supplements able to induce skin colour in last month before inclusion into the study. * Any clinically significant history of melanoma or skin cancer (including their immediate family), serious metabolic disease, digestive tract disease, liver disease, kidney disease, haematological disease or other illness that could interfere with the study. * History of severe reactions from exposure to sunlight (i.e., polymorphous light eruption) * Any surgery, chemical or physical treatment on the experimental area within the 12 months prior to the study or foreseeing it for the duration of the study. * Regular depilation of test area. * Planning a hospitalization during the study. * Impaired immune system due to autoimmune diseases, or use of immunosuppressive medication. * Mental incapacity that precludes adequate understanding or cooperation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of minimal erythema dose | 8 weeks | Increase of minimal erythema dose (MED) from baseline in test group in comparison to placebo group. Irradiation for determination of MED (J/cm2), will be performed with automated erythema tester Dermalight® 80 MED Tester (Dr Hoenle Medizintechnik GmbH, Germany; UVB 311 nm). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change of redness formation | 8 weeks | Decrease of redness formation following UVB irradiation in test group in comparison to placebo group. Redness measurements (CIE a\*) will be done before irradiation and after 24 hours post irradiation and variation of a\* calculated for each of the follow-up visits before and after 8 weeks of supplementation. The skin colour will be measured by Cortex Colorimeter DSM-4 (Cortex Technology ApS, Denmark). The colorimeter uses CIE L\* a\* b\* tridimensional colour space; a\* values (red-green axis) are an indicator of erythema/redness formation. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change of melanin index | 8 weeks | Change of melanin index (MI) following UVB irradiation in test group in comparison to placebo group. MI measurements will be done before irradiation and after 48 hours post irradiation and variation of MI calculated for each of the follow-up visits before and after 8 weeks of supplementation. MI will be measured by Cortex Colorimeter DSM-4 (Cortex Technology ApS, Denmark). The colorimeter uses CIE L\* a\* b\* tridimensional colour space. MI is a measure of pigmentation of the skin. |
Countries
Slovenia
Outcome results
None listed